CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; TELMISARTAN
✉ Email this page to a colleague
All Clinical Trials for Hydrochlorothiazide; Telmisartan
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00133185 ↗ | A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to | Completed | Boehringer Ingelheim | Phase 3 | 2004-03-01 | The primary objective of this trial is to compare the efficacy and safety of telmisartan 40 mg/hydrochlorothiazide 12.5mg (Micardis Plus) with that of losartan 50 mg/hydrochlorothiazide 12.5 mg, a reference AIIA combined with diuretic, in Taiwanese patients with mild to moderate hypertension. |
| NCT00144222 ↗ | Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy | Completed | Boehringer Ingelheim | Phase 3 | 2005-01-01 | The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) 40 mg in patients with essential hypertension who fail to respond adequately to telmisartan monotherapy. |
| NCT00146341 ↗ | Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg | Completed | Boehringer Ingelheim | Phase 3 | 2005-04-01 | To demonstrate that a fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg is superior to telmisartan 80 mg alone in patients, who fail to respond adequately to telmisartan 80 mg monotherapy, in lowering seated trough diastolic blood pressure after eight weeks of treatment. |
| NCT00153049 ↗ | 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension | Completed | Boehringer Ingelheim | Phase 2 | 2004-06-01 | 1. To investigate the dose response of the combination therapy, Telmisartan and Hydrochlorothiazide for the Japanese patients with Essential Hypertension. 2. To compare this dose response with that in the US study. |
| NCT00168779 ↗ | Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension | Completed | Boehringer Ingelheim | Phase 4 | 2005-09-01 | The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension. |
| NCT00208221 ↗ | Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes | Terminated | Institut de Recherches Cliniques de Montreal | Phase 3 | 2006-08-01 | The purpose of this study is to determine if a dose of ramipril combined with a normal dose of telmisartan 80 mg will be more effective than ramipril 20 mg in reducing microalbuminuria in hypertensive patients with diabetes. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Hydrochlorothiazide; Telmisartan
Condition Name
Clinical Trial Locations for Hydrochlorothiazide; Telmisartan
Trials by Country
Clinical Trial Progress for Hydrochlorothiazide; Telmisartan
Clinical Trial Phase
Clinical Trial Sponsors for Hydrochlorothiazide; Telmisartan
Sponsor Name
